Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4

被引:0
|
作者
Kristen C Hart
Scott C Robertson
Martha Y Kanemitsu
April N Meyer
John A Tynan
Daniel J Donoghue
机构
[1] University of California,Department of Chemistry and Biochemistry
来源
Oncogene | 2000年 / 19卷
关键词
FGFR; transformation; Stats; signal transduction;
D O I
暂无
中图分类号
学科分类号
摘要
The fibroblast growth factor receptor (FGFR) family members mediate a number of important cellular processes, and are mutated or overexpressed in several forms of human cancer. Mutation of Lys650→Glu in the activation loop of the FGFR3 kinase domain causes the lethal human skeletal disorder thanatophoric dysplasia type II (TDII) and is also found in patients with multiple myeloma, bladder and cervical carcinomas. This mutation leads to constitutive activation of FGFR3. To compare the signaling activity of FGFR family members, this activating mutation was generated in FGFR1, FGFR3, and FGFR4. We show that the kinase domains of FGFR1, FGFR3, and FGFR4 containing the activation loop mutation, when targeted to the plasma membrane by a myristylation signal, can transform NIH3T3 cells and induce neurite outgrowth in PC12 cells. Phosphorylation of Shp2, PLC-γ, and MAPK was also stimulated by all three ‘TDII-like’ FGFR derivatives. Additionally, activation of Stat1 and Stat3 was observed in cells expressing the activated FGFR derivatives. Finally, we demonstrate that FGFR1, FGFR3, and FGFR4 derivatives can stimulate PI-3 kinase activity. Our comparison of these activated receptor derivatives reveals a significant overlap in the panel of effector proteins used to mediate downstream signals. This also represents the first demonstration that activation of FGFR4, in addition to FGFR1 and FGFR3, can induce cellular transformation. Moreover, our results suggest that Stat activation by FGFRs is important in their ability to act as oncogenes.
引用
收藏
页码:3309 / 3320
页数:11
相关论文
共 50 条
  • [1] Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
    Hart, KC
    Robertson, SC
    Kanemitsu, MY
    Meyer, AN
    Tynan, JA
    Donoghue, DJ
    ONCOGENE, 2000, 19 (29) : 3309 - 3320
  • [2] FGFR3 and FGFR4 mutational analyses in thyroid carcinoma
    Serra, S.
    Cheng, S.
    Ezzat, S.
    Asa, S. L.
    LABORATORY INVESTIGATION, 2008, 88 : 110A - 111A
  • [3] FGFR3 and FGFR4 mutational analyses in thyroid carcinoma
    Serra, S.
    Cheng, S.
    Ezzat, S.
    Asa, S. L.
    MODERN PATHOLOGY, 2008, 21 : 110A - 111A
  • [4] Comparative analysis of FGFR1, FGFR3 and FGFR4 tyrosine kinase activities expressed as chimeric receptors in PC12 cells.
    Raffioni, S
    Bradshaw, RA
    FASEB JOURNAL, 1997, 11 (09): : A1057 - A1057
  • [5] Secreted FGFR3, but not FGFR1, inhibits lens fiber differentiation
    Govindarajan, V
    Overbeek, PA
    DEVELOPMENT, 2001, 128 (09): : 1617 - 1627
  • [6] FGFR3 and FGFR4 contribute to resistance in the therapy of colorectal cancer in vitro
    Erdem, Z. N.
    Heinzle, C.
    Sonvilla, G.
    Grasl-Kraupp, B.
    Holzmann, K.
    Grusch, M.
    Berger, W.
    Marian, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S552 - S552
  • [7] Redundant functions of Fgfr1, Fgfr2 and Fgfr3 in the development of the mid- and hindbrain
    Saarimaeki-Vire, J.
    Peltopuro, P.
    Blak, A.
    Lahti, L.
    Ornitz, D.
    Wurst, W.
    Partanen, J.
    INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, 2006, 24 (08) : 558 - 559
  • [8] FGFR3 and FGFR4 Do not Mediate Renal Effects of FGF23
    Liu, Shiguang
    Vierthaler, Luke
    Tang, Wen
    Zhou, Jianping
    Quarles, L. Darryl
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 19 (12): : 2342 - 2350
  • [9] Competition for ligands between FGFR1 and FGFR4 regulates Xenopus neural development
    Yamagishi, Masahiro
    Okamoto, Harumasa
    INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY, 2010, 54 (01): : 93 - 104
  • [10] Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype
    Li, Hua
    Martin, Aline
    David, Valentin
    Quarles, L. Darryl
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2011, 300 (03): : E508 - E517